Evercore ISI Issues Positive Forecast for Bio-Techne (NASDAQ:TECH) Stock Price

Bio-Techne (NASDAQ:TECH) had its price objective upped by Evercore ISI from $62.00 to $68.00 in a research report released on Thursday morning,Benzinga reports. Evercore ISI currently has an in-line rating on the biotechnology company’s stock.

Several other research firms also recently commented on TECH. Citigroup reaffirmed a “buy” rating and issued a $80.00 price target (up previously from $70.00) on shares of Bio-Techne in a research note on Wednesday. Zacks Research lowered shares of Bio-Techne from a “hold” rating to a “strong sell” rating in a research report on Wednesday, December 17th. UBS Group reiterated a “buy” rating and issued a $79.00 price target (up previously from $70.00) on shares of Bio-Techne in a report on Thursday. Deutsche Bank Aktiengesellschaft set a $72.00 price objective on Bio-Techne and gave the stock a “buy” rating in a research note on Friday, December 12th. Finally, Wells Fargo & Company lifted their target price on Bio-Techne from $59.00 to $70.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $72.31.

Bio-Techne Stock Performance

NASDAQ TECH opened at $65.86 on Thursday. The business’s 50 day moving average price is $63.25 and its 200-day moving average price is $59.25. Bio-Techne has a fifty-two week low of $46.01 and a fifty-two week high of $77.03. The company has a market cap of $10.26 billion, a P/E ratio of 129.14, a P/E/G ratio of 4.74 and a beta of 1.48. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.81 and a current ratio of 4.54.

Bio-Techne (NASDAQ:TECH) last announced its earnings results on Wednesday, February 4th. The biotechnology company reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.03. Bio-Techne had a net margin of 6.67% and a return on equity of 13.94%. The business had revenue of $295.88 million for the quarter, compared to the consensus estimate of $290.20 million. During the same quarter in the prior year, the firm posted $0.42 earnings per share. The business’s revenue for the quarter was down .4% on a year-over-year basis. Sell-side analysts predict that Bio-Techne will post 1.67 earnings per share for the current year.

Bio-Techne Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, February 27th. Stockholders of record on Monday, February 16th will be issued a $0.08 dividend. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Friday, February 13th. Bio-Techne’s dividend payout ratio (DPR) is currently 65.31%.

Institutional Trading of Bio-Techne

A number of institutional investors have recently made changes to their positions in the business. Blue Trust Inc. raised its stake in shares of Bio-Techne by 109.7% in the third quarter. Blue Trust Inc. now owns 453 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 237 shares during the last quarter. Danske Bank A S purchased a new stake in Bio-Techne in the fourth quarter valued at approximately $29,000. eCIO Inc. acquired a new position in Bio-Techne in the 4th quarter worth approximately $30,000. Allworth Financial LP raised its position in Bio-Techne by 68.1% during the 2nd quarter. Allworth Financial LP now owns 612 shares of the biotechnology company’s stock worth $31,000 after buying an additional 248 shares during the last quarter. Finally, Measured Wealth Private Client Group LLC purchased a new position in Bio-Techne during the 3rd quarter worth approximately $32,000. Institutional investors and hedge funds own 98.95% of the company’s stock.

Trending Headlines about Bio-Techne

Here are the key news stories impacting Bio-Techne this week:

• Positive Sentiment: Q2 results beat analysts: adjusted EPS of $0.46 topped estimates and revenue of ~$296M beat consensus; operating margin improved materially (~244 bps). This supports near‑term profitability momentum. Reuters: Bio-Techne beats quarterly estimates
• Positive Sentiment: Company outlook: management signaled mid‑single‑digit underlying growth for fiscal 2026 with margin expansion and “cell therapy normalization” ahead — a constructive forward signal for revenue recovery and margin leverage. MSN: Guidance and outlook
• Positive Sentiment: Dividend declared: Board approved a $0.08 quarterly dividend (payable Feb. 27) — modest but signals capital return discipline. PR Newswire: Dividend announcement
• Positive Sentiment: Analyst moves: Evercore raised its price target from $62 to $68 (in‑line rating), and Citi reiterated a Buy with an $80 target — mixed but includes higher targets that could support upside. Benzinga: Evercore note
• Neutral Sentiment: Conference call / transcripts available — contains management commentary that investors will parse for cadence on cell‑therapy recovery and margin timing. Seeking Alpha: Earnings call transcript
• Neutral Sentiment: Industry developments referenced in roundups (new ECM tech, lab M&A) could be relevant longer term but are not immediate drivers of TECH’s stock. BioTechniques: industry bi‑weekly
• Negative Sentiment: Top‑line softness: reported revenue was roughly flat organically and down ~0.4% YoY — investors disappointed by lack of stronger growth despite the beat. PR Newswire: Q2 results release
• Negative Sentiment: Valuation and expectations: TECH trades at a high P/E and elevated PEG, which increases sensitivity to any growth disappointments and may pressure the stock despite margin gains.

Bio-Techne Company Profile

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.